JP2024515459A5 - - Google Patents

Info

Publication number
JP2024515459A5
JP2024515459A5 JP2023558203A JP2023558203A JP2024515459A5 JP 2024515459 A5 JP2024515459 A5 JP 2024515459A5 JP 2023558203 A JP2023558203 A JP 2023558203A JP 2023558203 A JP2023558203 A JP 2023558203A JP 2024515459 A5 JP2024515459 A5 JP 2024515459A5
Authority
JP
Japan
Prior art keywords
sequence
approximately
composition according
identity
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515459A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/071937 external-priority patent/WO2022232790A1/en
Publication of JP2024515459A publication Critical patent/JP2024515459A/ja
Publication of JP2024515459A5 publication Critical patent/JP2024515459A5/ja
Pending legal-status Critical Current

Links

JP2023558203A 2021-04-27 2022-04-26 アフリベルセプトをコードするaav2バリアントを使用する眼疾患の治療方法 Pending JP2024515459A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163180646P 2021-04-27 2021-04-27
US63/180,646 2021-04-27
PCT/US2022/071937 WO2022232790A1 (en) 2021-04-27 2022-04-26 Methods of treating ocular diseases using aav2 variants encoding aflibercept

Publications (2)

Publication Number Publication Date
JP2024515459A JP2024515459A (ja) 2024-04-10
JP2024515459A5 true JP2024515459A5 (enExample) 2025-04-28

Family

ID=81984711

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558203A Pending JP2024515459A (ja) 2021-04-27 2022-04-26 アフリベルセプトをコードするaav2バリアントを使用する眼疾患の治療方法

Country Status (9)

Country Link
US (1) US20240197915A1 (enExample)
EP (1) EP4329721A1 (enExample)
JP (1) JP2024515459A (enExample)
KR (1) KR20240005764A (enExample)
CN (1) CN117222400A (enExample)
BR (1) BR112023019056A2 (enExample)
CA (1) CA3215855A1 (enExample)
MX (1) MX2023012410A (enExample)
WO (1) WO2022232790A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
KR20260005446A (ko) 2024-07-03 2026-01-12 김성훈 김치 제조 장치
KR20260006393A (ko) 2024-07-04 2026-01-13 김성훈 가정용 김치 제조 장치
TW202607144A (zh) * 2024-07-16 2026-02-16 美商愛德維仁生物科技公司 使用編碼阿柏西普(aflibercept)之aav2變異體治療眼部新生血管性疾病的方法
WO2026160680A1 (ko) * 2025-01-24 2026-07-30 연세대학교 산학협력단 망막 세포 표적화 아데노-관련 바이러스 변이체 adn 및 그의 용도
WO2026160681A1 (ko) * 2025-01-24 2026-07-30 연세대학교 산학협력단 망막 세포 표적화 아데노-관련 바이러스 변이체 kap 및 그의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3693025T3 (da) * 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
ES2908467T3 (es) * 2016-04-29 2022-04-29 Adverum Biotechnologies Inc Evasión de anticuerpos neutralizantes por un virus adenoasociado recombinante
CN117531025A (zh) * 2016-06-16 2024-02-09 阿德夫拉姆生物技术股份有限公司 使用aav2变体和阿柏西普治疗amd
KR102616820B1 (ko) 2017-03-17 2023-12-21 애드베룸 바이오테크놀로지스, 인코포레이티드 향상된 유전자 발현을 위한 조성물 및 방법
TW201904610A (zh) * 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2020180951A1 (en) * 2019-03-04 2020-09-10 Adverum Biotechnologies, Inc. Sequential intravitreal administration of aav gene therapy to contralateral eyes
JP7893739B2 (ja) 2019-09-11 2026-07-23 アドヴェラム バイオテクノロジーズ, インコーポレイテッド アフリベルセプトをコードするaav2バリアントを使用する眼内血管新生疾患を処置する方法
KR20260017004A (ko) * 2019-09-11 2026-02-04 애드베룸 바이오테크놀로지스, 인코포레이티드 아플리베르셉트를 코딩하는 aav2 변이체를 사용하여 안구 신생혈관 질환을 치료하는 방법
CN114375195A (zh) 2019-09-11 2022-04-19 阿德夫拉姆生物技术股份有限公司 使用编码阿柏西普的aav2变体治疗眼新血管疾病的方法

Similar Documents

Publication Publication Date Title
JP2022547541A5 (enExample)
JP2025506383A5 (enExample)
JP2025506681A5 (enExample)
FI4027983T3 (fi) Silmän neovaskulaaristen sairauksien hoito afliberseptiä koodaavilla aav2-varianteilla
US20240327481A1 (en) Growth differentiation factor 15 fusion proteins
CN100389820C (zh) 含肉毒神经毒素的治疗剂
JP2024016207A5 (enExample)
JP2021503914A5 (enExample)
US10098905B2 (en) Immunomodulating gene therapy
RU2018142768A (ru) Варианты капсидов аденоассоциированного вируса и способы их применения
JP2022522776A5 (enExample)
JP2022511776A5 (enExample)
JP2020537637A5 (enExample)
JP2020526514A5 (enExample)
JP2021511030A5 (enExample)
JP2024517143A5 (enExample)
JP2022512589A5 (enExample)
JP2023545229A5 (enExample)
JP2025509568A5 (enExample)
MX2024010002A (es) Metodo para reducir la fluctuacion del cst en amd neovascular mediante un virus adenoasociado recombinante
CN101213305A (zh) 转基因在哺乳动物中枢神经系统中的可调控型表达
CA3178591A1 (en) Immunosuppressive agents and viral delivery re-dosing methods for gene therapy
JP2024511024A (ja) 21-ヒドロキシラーゼ欠損症の遺伝子治療
JP2022523050A5 (enExample)
JP2022518354A5 (enExample)